Many statisticians have contributed to studies of the HIV epidemic and progression to AIDS. They have developed new statistical methodology, where needed, to address HIV-related issues. The transfer of methods from one area to another often involves a substantial delay. This paper points to methods that were developed in the HIV context and have either already found applications in other areas of medical research or have the potential for such applications, with the hope that this will promote a speedier transfer of the research methods. Among the new tools that HIV studies have placed firmly into the pool of statistical methods for medical research are the methods of back-calculation, methods for the analysis of retrospective ascertainment data and methods of analysis for the combined data from clinical trials and associated longitudinal studies. Notions that have been stimulated substantially are use of surrogate endpoints in clinical trials and screening blood products by the use of pooled serum samples. Research activity in many other areas has been boosted substantially through contributions motivated by HIV/AIDS studies. Noteworthy examples are analyses for doubly-censored lifetime data and methods for assessing vaccines for transmissible diseases.
Introduction
Emergence of the lethal health condition AIDS and recognition that it is caused by a virus transmitted between humans attracted researchers from many disciplines, including many statisticians. We take a look at the impact that this substantial research effort has had on statistical methodology for medical research. Factors that contribute to this impact are the enhanced interaction with researchers from other disciplines, the unique challenges of HIV/AIDS and the fact that statisticians came to this area from varied backgrounds, bringing with them a broad range of experience with statistical applications in other fields.
The statistical literature concerned with HIV/AIDS is very large and we make no attempt to provide a complete review of biostatistical methods used in AIDS studies. Other general reviews have appeared over the last decade, [1] [2] [3] as have more specific reviews in some of the methodological areas described below. Our aim in adding to this list is to highlight ways in which medical statistics has been enhanced by statisticians working on HIV/AIDS studies. The focus is on novel extensions and adaptations of existing statistical methodology to address AIDS issues and new methods developed in the context of AIDS that are applicable in other areas. There are already applications of methods developed for HIV/AIDS to other diseases, and we mention some of these here. Such applications are testimony to the wider applicability of the methods. However, there is usually a considerable delay in the transfer of methods from one area to another and so highlighting methods that have the potential for useful applications in other areas is an important purpose of this paper, with the hope that this will facilitate the transfer of the methodology.
We call the time from infection with HIV until diagnosis with AIDS the incubation period, and refer to its distribution as the incubation distribution. One of the first problems statisticians addressed was estimating the incubation distribution and the related problem of estimating the time until death. In the terminology of survival analysis, the incubation period and the time from AIDS diagnosis until death are 'lifetimes' and we begin, in Section 2, with a look at new issues contributed to survival analysis through AIDS research. Simultaneously, there was a focus on estimating how many people had been infected and predicting the number of AIDS cases we would see in the future. The methods and their wider application are discussed in Section 3. Additional issues of central importance are the monitoring of disease progression through markers and the assessment of therapies. These topics are taken up under the headings of longitudinal studies and clinical trials in Sections 4 and 5, respectively. The fact that HIV is transmissible suggests that there is an overlap in methodology for AIDS research and the study of infectious diseases. This theme is explored in Section 6. Two challenging issues are control of HIV transmission and early detection of HIV infection, which leads us to consider methodology for vaccine studies and methods concerned with screening for a disease with low prevalence in Section 7.
Analysis of survival data
Classical survival analysis is concerned with inference about the distribution of the time until some event occurs, the 'lifetime', when observed lifetimes are subject to rightcensoring. That is, some of the independent lifetimes are observed and for others it is only known that they are larger than some specific value. Entry into the study cohort can occur at random time points. Over the years this classical setting has been extended to include left-censoring, interval-censoring, truncation and filtering, so that survival analysis now refers more correctly to the analysis of 'incompletely observed lifetimes'.
The problem of making inferences about the incubation distribution is clearly important and has received a lot of attention. It is akin to the mainstream issue in survival analysis, with the incubation period being the lifetime of survival analysis. Three features often obtain in the HIV context that differ from the classical survival analysis setting. First, we often have an observational study, rather than a planned cohort study. Second, entry into the study is by diagnosis, either of HIV infection or AIDS, which is not the beginning of the associated lifetime. Finally, various forms of censoring and truncation arise because the time of infection is usually unobserved and individuals enter the study sample in a variety of ways. We take a look at some of these differences and how they have contributed to further development of statistical methodology.
New sampling schemes
The earliest attempts to estimate the incubation distribution focused on cases of AIDS that were acquired by blood transfusion, because the time of infection could be determined by the time when they received contaminated blood. The study samples for such estimation of the incubation distribution were typically recruited as follows. Choose a time t for which it is believed that data on AIDS diagnoses are essentially complete. That is, allowance is made for reporting delays. From all individuals diagnosed with AIDS by time t, select those for whom it can be determined that they acquired the HIV infection from a blood transfusion. The data set then consists of the incubation periods for those individuals with medically acquired HIV infection who were diagnosed with AIDS prior to time t. This sampling scheme excludes lifetimes that are not completed by time t. An analysis must be based on the method used to sample these incubation periods or it will result in biased inferences, because shorter incubation periods tend to be over-represented in the sample. Kalbfleisch and Lawless 4 refer to this type of sampling as retrospective ascertainment data.
Early contributions to the development of analyses for this type of data include those of Lui et al., 5 Medley et al., 6 Lagakos et al. 7 and Kalbfleisch and Lawless. 4 Retrospective ascertainment data is survival data if we include in 'incompletely observed lifetimes' the situation where only lifetimes that are 'lived' entirely before time t are included in the sample. Like classical survival analysis, inferences about the incubation distribution from retrospective ascertainment data have been extended to include regression, to allow the distribution to depend on covariates and risk factors, see for example Kalbfleisch and Lawless. 8 The hazard function plays a central role in survival analysis. Lagakos et al. 7 show that with the extension to retrospective ascertainment data it is useful to introduce the new notion of a reverse-time hazard function. This function has the interpretation of a hazard function when viewed backwards in time from the time of AIDS diagnosis. Just like a standard hazard function, a reverse-time hazard function uniquely determines the survival distribution. The regression proposed by Kalbfleisch and Lawless 8 is based on the reverse-time hazard function.
One might ask 'why not use data on all individuals infected with HIV by a transfusion?'. The answer is that the number of individuals who had transfusions is extremely large and it is not feasible to follow up and test every one who had a transfusion during the period when there was a risk of infection. However, a good HIV surveillance register does provide data on individuals infected with HIV by transfusion who do not yet have an AIDS diagnosis. In the extreme case, where every individual infected by a transfusion up to time t is detected, the data set has precisely the form of classical survival analysis. As observed by Motika et al., 9 in practice we expect to have a survival time for only some of the individuals infected with HIV by transfusion but without an AIDS diagnosis. The analysis required for such a set of survival times differs from classical survival analysis in that the analysis requires some assumptions about the way HIV diagnoses arise. Motika et al. 9 propose a model for the intensity of HIV diagnosis that incorporates both a population screening intensity and a symptom-related hazard.
We see that HIV-related methods have extended the domain of application of survival analysis to different kinds of incomplete observations. The methodology for this new way of sampling individuals is clearly relevant to hepatitis C, since its mode of transmission is similar to HIV and it also has a long incubation period. However, similar sampling schemes apply to other diseases. For example, Farrington 10 adapted the methodology developed for estimating the incubation period of AIDS to estimate the distribution of the time from infection with measles until the onset of sub-acute sclerosing panencephalitis. He was thereby able to show that the increase in these time intervals observed in England and Wales over the years 1970-1989 can be explained by the decline in measles incidence following the introduction of mass vaccination in 1968.
Retrospective ascertainment data also arise in the HIV/AIDS context when considering data on reporting delays. A diagnosis is not entered onto the surveillance register, and therefore is not known to have occurred, until it arrives at the surveillance centre. This can involve a delay measured in months. Here interest lies in estimating the distribution of the time from diagnosis until entry onto the surveillance register, primarily because this distribution is needed to adjust AIDS incidence data for reporting delays; see below. However, analysis of reporting delay data has also been undertaken to identify sources of delays. These methods are clearly relevant to reporting delays in surveillance registers of all notifiable diseases. It is important to adjust surveillance data for reporting delays if the system is used to monitor disease incidence and to indicate the start of an epidemic. The methods developed to adjust AIDS registers for reporting delays are applied to reporting delays for multiple sclerosis diagnoses in Denmark by Esbjerg et al.
11 who find that reporting delays depend on calendar time and age at the time of first symptoms. The estimated delay distributions are then used to adjust the incidence of multiple sclerosis diagnoses for reporting delays to allow meaningful assessment of recent incidence of diagnoses.
Censored and truncated data
About three dozen of the papers on methods for the analysis of censored and truncated lifetime data, that appeared in mainstream international statistics journals in the last decade, are motivated by HIV studies. It has given this topic a very substantial boost. Methods for making statistical inferences from censored lifetime data are essential in the HIV context because we are often interested in the distribution of the time duration between two events where the exact times of these events are not observed. For example, the two events might be (i) infection and AIDS diagnosis, or (ii) becoming infectious and developing detectable HIV antibody, or (iii) being infected and infecting a sexual partner. Both the initiating event and the subsequent event are typically subject to censoring, because tests to determine whether these events have occurred to individuals of a cohort are typically conducted on individuals on an occasional basis or at a sequence of regular time points. In particular, the urgent need to estimate the incubation distribution was initially aided by data on stored blood samples collected routinely from haemophiliacs and from members of a large cohort that was set up to study hepatitis B. Some of these individuals became infected with HIV and the retrospective tests on their blood samples provide times of the last sample that tested negative for HIV and the first sample that was positive. Therefore the start of the time of seroconversion for these individuals was interval-censored. In observational HIV studies individuals typically are included only if diagnosis has occurred, and been reported, before the time of analysis. This implies a truncation because data on individuals with longer incubation times, or longer reporting delays, are not included in the study.
The need to estimate the distribution of the time between two HIV-related events has drawn considerable attention to the self-consistency algorithm of Turnbull 12 for computing the empirical distribution function from data in which the end of the lifetime is interval-censored and truncation is present. To meet requirements common in HIV data, DeGruttola and Lagakos 13 extend the algorithm to allow the start of the lifetime to be interval-censored as well. They describe such lifetime data as doubly-censored. In Kim et al.
14 this non-parametric estimation of the lifetime distribution is extended to allow 17 consider the use of proportional hazard models. In the HIV context it is often appropriate to consider the times between three, or more, events. For example, Gómez and Lagakos 18 and Sun 19 consider estimation of the distribution of both the time until infection and the incubation distribution when both the start and the end point of the incubation period are subject to censoring, while DeGruttola et al. 20 consider the duration until infection, the duration of the incubation period and the duration of reporting delay. Similar estimation problems arise in the progression of other diseases, such as cancers, where stages of disease progress are identified, see Leung and Elashoff. 21 
Disease incidence assessment
The importance of monitoring and projecting the extent of new cases of HIV and AIDS led to the development and enhancement of a variety of statistical techniques for assessing disease incidence. Of particular interest is methodology for the analysis of disease surveillance data, as is collected by health authorities. Surveillance data on the occurrence of new AIDS cases over time generally arises from the compulsory reporting of new diagnoses to a central registry, and can be used not only to assess and project AIDS incidence trends, but also to reconstruct unobservable patterns of HIV incidence. Since a comparable progression from asymptomatic to symptomatic disease exists in many other contexts, incidence data on the occurrence of other diseases has been used to reconstruct underlying subclinical disease incidence trends using statistical methodology that was originally developed specifically to deal with AIDS surveillance data. A further class of statistical techniques for assessing disease incidence is based on data from cross-sectional disease prevalence surveys. Statistical analysis of trends in HIV prevalence over time and age has been used to assess trends in HIV incidence for specific subpopulations. Since serial prevalence data of this type can provide similar information for many other irreversible conditions, methodology developed in the context of HIV has contributed to the development of statistical techniques applicable to other diseases. In the following sections we review statistical issues arising in the assessment of HIV/AIDS incidence from surveillance data and prevalence surveys, and point to the broader applicability of such techniques. Although other more direct methods of HIV incidence assessment have also been used, for example based on cohort studies, we concentrate here on indirect methods that have required greater statistical development.
Back-calculation of incidence trends
There have been many implementations of back-calculation, also called backprojection, stemming from early developments applicable to AIDS. [22] [23] [24] The basic idea is to use known information about the time it takes to progress from one disease state to another, together with incidence information on the latter disease state, to derive incidence information on the former disease state. In the context of AIDS, this means using external information about the time d from infection with HIV to the diagnosis of AIDS, in the form of an incubation probability function f t (d ), together with the sequence of AIDS diagnosis counts Y ¼ fY t g for time periods t ¼ 1, . . . , T. Here, the indexing of the incubation distribution by time allows for secular trends resulting from changes in treatment over time. 24 These two ingredients, the incubation distribution and the AIDS incidence data, are used to obtain information about the unobserved sequence of HIV infection counts H ¼ fH t g. Usually the problem is formulated by assuming Y is a vector of (possibly over-dispersed) Poisson random variables with means m, and focusing on estimation of mean HIV incidence l ¼ EðHÞ using the basic convolution relationship
or in matrix notation, the linear model m ¼ Xl, where X is a known design matrix with elements determined by the incubation distribution according to the convolution equation (3.1). An alternative to estimation of l based on the above Poisson formulation, is estimation of H based on a related multinomial formulation, 24, 25 however, the two approaches tend to produce qualitatively similar results.
With these ingredients the problem reduces to a deconvolution problem which in principle can be solved by fitting a linear-Poisson model. In practice, however, T will be large, so that the deconvolution problem is high-dimensional and ill-posed. 26 A consequence is that incidence estimates exhibit substantial instability, including implausible oscillations over time and violation of positivity constraints. Statistical developments have therefore focused on methods for overcoming such instability, both in terms of the resulting estimates and in terms of the computation process itself. One way to stabilize estimates is to reduce the dimensionality of the problem by parameterizing l, using fully parametric models, 27 or weakly parametric models based on step-functions that remain constant over long periods of time. 28 Another approach is to retain the flexibility of the unstructured model by imposing only a smoothness requirement. The use of penalized likelihood and empirical Bayes adaptations of the basic Poisson likelihood problem have been prominent in this context, 24, [29] [30] [31] which in turn are related to earlier smoothing methods, particularly the use of moving average smoothing within the EM algorithm. 32, 33 The EM algorithm has proved popular in back-calculation methodology partly because the problem can be formulated very naturally as a missing data problem, in which the HIV counts constitute the unobserved complete data, and partly because it provides a stable method of computation that automatically ensures positivity of incidence estimates despite the linear-Poisson structure of the model.
Estimates of l resulting from the above back-calculation methods can be used for qualitative assessment of historical incidence trends over time, such as whether or not incidence has peaked, as well as assessment of cumulative incidence, leading to estimates of how many individuals are currently infected. A further use is in short-term projection of future AIDS incidence, based on evaluation of the convolution relation (3.1) at times beyond T, using assumptions about future HIV incidence in the short term. Since there are many other contexts where comparable data are available, the above methodology, and related variations, has found application in a variety of non-AIDS settings. One of the most prominent such applications is in a series of papers on incidence assessment for bovine spongiform encephalopathy (BSE), or 'mad cow disease', the causative agent for the outbreak of variant Creutzfeldt-Jakob Disease (vCJD) in Great Britain. Using central registry data on the incidence of symptomatic BSE in cattle, together with information about the transmission dynamics and the progression of BSE subsequent to infection with its aetiological agent, back-calculation methodology was extended to reconstruct past numbers of infections. 34, 35 Such estimates were crucial to quantitative assessment of the BSE epidemic, and enabled prediction of the decline and subsequent fadeout of the epidemic. 36 Furthermore, when combined with mathematical models of the transmission dynamics of BSE, back-calculation incidence estimates provided a means of estimating the basic reproductive number of BSE over time. 37 This enabled confirmation that the basic reproduction number had fallen to well below 1 subsequent to preventive bans on cattle products, thus confirming that BSE was unable to reach endemic proportions.
The original back-calculation methodology, as described above, was developed for reconstructing trends in incidence over time, under the implicit assumption of agehomogeneity. For some diseases, however, it makes more sense to consider the converse problem, of reconstructing age-specific trends in incidence under the assumption of timehomogeneity. For example this approach was applied to data on the ages of occurrence of clinical Haemophilus influenzae type b (Hib) infection in children, to reconstruct agespecific incidence information on subclinical Hib infection using an adaptation of the above back-calculation methodology. 38 However, in many contexts including AIDS, neither age-nor time-homogeneity are reasonable assumptions, and methodology for bivariate reconstruction of age-and time-specific disease incidence has been developed. Such methodology is based on an age-specific extension of the basic convolution equation described above, with both HIV and AIDS incidence, as well as the incubation distribution, being age-dependent
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In the context of AIDS this has allowed age-and time-specific modelling based on both multiplicative and non-multiplicative models 31, 33 and has for example led to the observation that the relative risk of HIV infection has steadily increased among younger individuals over time. 31, 39 This methodology was subsequently adapted to back-calculation of age-specific cancer incidence, based on registry data on age-specific cancer mortality. 40 The above examples illustrate the contribution that AIDS back-calculation methodology has made in more general contexts. Further examples include the assessment of hepatitis C virus incidence based on mortality data from hepatocellular carcinoma resulting from hepatitus C, 41 and assessment of multiple sclerosis onset rates using data on the diagnosis of symptomatic multiple sclerosis. 42 In all applications of backcalculation, whether in AIDS or other diseases, a number of important caveats remain. Most notable is the dependence on external information about the time between the unobservable and observable disease states of interest. Since this distribution must be assumed known for back-calculation to be applicable, good quality external information is critical, for example from cohort studies. The sensitivity of HIV incidence reconstructions obtained from back-calculation is well known, 24, 43 stemming from sensitivity to the assumed incubation distribution, and this has meant that the method is primarily useful for assessing qualitative trends. A further limitation of the method is that it provides very Advances in medical statistics arising from the AIDS epidemic 123 little information about incidence rates in the very recent past, however, fortunately shortterm projections tend to be fairly insensitive to recent incidence rates. Finally, we note that incidence data are often subject to reporting delays and require adjustment prior to application of the method of back-calculation, see Section 2.1.
Analysis of serial prevalence data
It is well known that a single age-specific prevalence sample for an irreversible disease can be used to provide information about age-specific incidence under an assumption of time-homogeneity. 44 Extensions of this methodology have been developed in the context of HIV and other diseases, in order to allow age-and time-specific disease incidence assessment based on multiple age-specific prevalence surveys taken serially over time. Such data are particularly useful for HIV incidence assessment in developing countries where centralized registries for the collection of surveillance data are less common, 45, 46 and are also useful for specific population sub-groups, for example in women based on anonymous HIV testing of mothers giving birth. 47 A large family of sources of HIV prevalence information is described by Brookmeyer and Gail 24 (Table 3 .6) and a number of data sources and methods applicable to USA are described by Karon et al. 48 Despite the usefulness of such data in the context of HIV, the first flexible method for age-and time-specific incidence estimation on the basis of age-and time-specific prevalence data was developed in the context of toxoplasmosis. 49 A major limitation of this method, however, is its restriction to diseases that do not influence the chance of being included in a cross-sectional survey -thus, for example, it excludes diseases with increased mortality. Developments in this area motivated by HIV have focused on more widely applicable methods that make allowance for differential mortality and other forms of differential inclusion. While initial applications demonstrated the potential use of serial prevalence data for assessing age-and time-specific HIV incidence, 45, 46 the work of Ades and Medley 47 in the context of HIV prevalence data on women giving birth, gives the first flexible method for analysing serial prevalence data adjusting for the effect of differential inclusion. A subsequent detailed discussion and analysis 50 of the relationship between age-and time-specific incidence, prevalence and differential inclusion demonstrates that trends in serial prevalence are not easily interpreted in terms of incidence trends. Such interpretation requires detailed consideration of the relationship between the age-and time-specific incidence rate lða, tÞ and the age-and time-specific prevalence P(a, t). A link between these two quantities depends on the so-called 'relative inclusion rate' Èða, t, dÞ, which is the relative risk of an infected individual being included in the sample compared to an uninfected individual (as a function of age a, calendar time t and the time d since disease onset). This leads to an underlying relationship Pða, tÞ ¼ Fðl, ÈÞ ð 3:3Þ which has been used in a number of analogous forms by a variety of authors. 47, 51, 52 Serial disease prevalence data correspond to observation of N at , the number of individuals of age a included in the prevalence sample at calendar time t, and Z at the corresponding number of individuals who were disease prevalent at age a and time t. Since Z at is binomial (N at , P(a, t)), the incidence l can in principle be estimated using maximum likelihood applied to the binomial model. However, this is complicated by the fact that the model does not have a generalized linear form, and the fact that similarly to back-calculation, the unstructured model is subject to instability. Ades and Medley 47 overcame these problems by the use of a step-function parametrization that allows both multiplicative and non-multiplicative age-time incidence. This methodology was extended by Marschner 51 in the context of toxoplasmosis data using non-parametric models with smoothing induced by a roughness penalty on the binomial likelihood function. Independently, similarly motivated methodology was subsequently developed and applied to HIV prevalence surveys by Brunet and Struchiner. 52 Just as the incubation distribution is the link between AIDS incidence and HIV incidence in back-calculation, the relative inclusion rate provides the link between serial HIV prevalence and HIV incidence. Thus, similarly to back-calculation, incidence assessment based on serial prevalence data is subject to sensitivities arising from a lack of knowledge of factors affecting inclusion in the prevalence sample. In general, methodology for analysing serial prevalence data works best when good information is available about the inclusion mechanisms, so that the only unknown in equation (3.3) is the incidence l.
We have focused here on the interpretation of prevalence data from irreversible indicators of infection such as HIV antibody testing, however, prevalence of other temporary indicators can also be used to obtain incidence information. For example, if it is known how long a temporary virological or immunological marker is present after infection, then the standard relationship between incidence, prevalence and duration can be used to yield recent incidence information from a single prevalence survey. This idea was proposed and successfully applied in the context of HIV 53, 54 but is relevant for other health conditions. The use of prevalence data on HIV markers to estimate HIV incidence was also considered by Satten and Longini, 55 in which serial prevalence of CD4 count stages was used to reconstruct past patterns of HIV incidence.
The wider applicability of methods discussed above stems from the fact that in many disease contexts prevalence data are more readily collected and less expensive than longitudinal cohort data. Thus, while these and other indirect methods of incidence assessment, such as back-calculation, are subject to uncertainties about inclusion mechanisms or the incubation distribution, they provide a cost-effective source of information on qualitative incidence trends and plausible scenarios. Interestingly, some of the sources of uncertainty associated with serial prevalence data and back-calculation estimates are complementary: back-calculation produces incidence estimates that are uncertain in the recent past, whereas serial prevalence data yields estimates that are uncertain in the distant past but more certain in the recent past. This led Ades and Medley 47 to suggest the possibility of joint analysis of serial prevalence data and disease surveillance data, however, such methodology does not seem to have been developed in the literature.
Analysis of longitudinal data
Immunological and virological markers of HIV infection play an important role in assessing both the natural history of disease and the response to treatment. The most common markers of HIV infection are CD4 cell counts, a marker of immune function, and HIV viral load, as measured by the concentration of HIV RNA in plasma. Interest in these and other markers of HIV infection has led to a variety of longitudinal data Advances in medical statistics arising from the AIDS epidemic 125 structures, arising from repeated measurement of marker levels over time within individuals. Statisticians have devoted substantial effort to methodological developments allowing appropriate analysis of such data, taking due account of such issues as longitudinal dependence structures and measurement error adjustment. The goals of such analyses are varied and depend on the context in which the data are collected. Longerterm longitudinal data, in which HIV markers are measured on a monthly or yearly basis, generally arise from clinical trials or cohort studies. Such studies can be used to quantify components of variation in marker values, which is important for defining a level of change that can be considered not to be due to random fluctuation alone. They also allow assessment of the interrelationship between multiple markers or between markers and other outcomes such as time to clinical disease progression, as well as allowing the development of strategies for individual prediction of future marker levels on the basis of past observations. Short-term measurement, in which HIV viral load and other markers are measured on a daily basis over a period of weeks, lead to longitudinal data that have been widely used to investigate basic issues in viral dynamics, such as the manner in which the virus replicates within the body. AIDS-related longitudinal methodology has far wider relevance, because longitudinal data are collected for many other diseases, and has therefore provided a substantial boost to an already highly active field of research.
Boscardin et al. 56 have provided a nice review of a number of longitudinal methods for AIDS marker data, particularly random effects based methods appropriate for modelling longer-term repeated measures collected over months or years. The basic idea of the primary methods reviewed by these authors is to model repeated measures as the sum of a mixed model for between-subject differences, and an additional stochastic process that specifies the extent to which the marker trajectory over time varies stochastically about an underlying deterministic subject-specific path. This allows within-subject variability to be partitioned into correlated random error and pure measurement noise. Thus, the general form of many longitudinal models that have been used successfully for AIDS marker data is
where t ij is the time of the jth marker measurement on the ith individual; the Y 's are the (possibly transformed) marker levels such as CD4 cell counts or HIV viral load levels; the X 's and Z's make up the design matrices for fixed and random effects; the W 's are values of an appropriately chosen zero mean stochastic process; and the "'s are independent random errors. The idea of adding a stochastic process to a mixed model for analysing longitudinal data was originally proposed in non-AIDS contexts, see for example Diggle. 57 Nonetheless, the importance of longitudinal analysis of AIDS marker data, and the subsequent effort applied to this problem, have led to an array of AIDS-motivated expansions of this methodology. We refer the reader to Boscardin et al. 56 for a more complete discussion of a variety of methods based on both Bayesian and non-Bayesian models, in both mixed model settings and the more general context described above. Of particular note is the study of varied forms for the stochastic process W(t), based on Gaussian processes with various covariance structures, see for example Berman, 58 Galai et al. 59 A particularly flexible approach, originally proposed by Taylor et al., 60 specifies W(t) to follow an Integrated Ornstein-Uhlenbeck (IOU) process. The advantage of this approach is that it includes a wide range of models as special cases, from random effects 126 NG Becker and IC Marschner through to Brownian motion, with the fitted IOU process modulating the extent to which individual marker trajectories tend to 'track', or retain a constant slope. The flexibility afforded by this approach is advantageous as the choice of covariance structure can have important influences on individual level predictions of longitudinal markers. 61 An additional advantage is that the model extends naturally to bivariate modelling of longitudinal outcomes, so that interrelationships between markers, such as CD4 counts and viral load, can be modelled longitudinally. 62 While equation (4.1) is quite general, it is still based on an underlying linear structure. Methodology for non-linear longitudinal modelling has also received substantial motivation from AIDS marker problems, and has particularly involved methods based on smoothing. Some of these developments have extended the linear approach by replacing the linear mixed model component of equation (4.1) with a smooth function of time determined by cubic spline models, 63 ,64 kernel smoothing methods 65 or local methods. 66, 67 While longer-term AIDS marker data have motivated non-linear models based on smoothing, short-term HIV viral dynamics have provided motivation for longitudinal models based on specific non-linear forms derived from dynamic models for HIV replication within the body. The goal of these models is to describe the interaction between HIV virions and the immune system host cells. By fitting such models to data on repeated measurements of HIV viral load during the days following antiviral treatment, fundamental advances have resulted in our understanding of the way HIV replicates within the body. 68, 69 While earlier analyses of these longitudinal data were based on crude model fitting procedures that did not account for dependence structures within the data, later more complex analyses provided an important area of application for hierarchical non-linear mixed effects models. 70 Such longitudinal analyses (see for example Wu et al., 71 Wu and Ding
72
) have used underlying non-linear models to describe the way HIV viral load changes after treatment, and made use of non-linear mixed models to estimate rate parameters within these models, such as virion clearance rates. It is true that the models used in these viral dynamics studies are fairly specific to the dynamics of HIV infection and that the non-linear longitudinal methodology was developed in other contexts, particularly in pharmacology studies. Nonetheless these applications are of wider interest in that highly complex mathematical models often make use of crucial parameter values determined on the basis of very crude analyses. Longitudinal analysis of HIV viral dynamics studies therefore provide a nice illustration of the use of appropriate statistical analysis for determining the parameter values in dynamic models, and serve as a general motivation for the interplay between mathematical modelling and statistical analysis in the building of models for dynamic systems.
Many data sets on HIV-infected individuals provide rich information on both biological markers and times to events. As a consequence, a number of authors have studied methodology for joint analysis of longitudinal and censored survival data. This is another example of an area where methods initiated in non-AIDS contexts have received substantial contributions and expansions from AIDS-motivated research. Joint analysis is desirable because estimates of the effect of markers, such as CD4 and viral load, on time to clinical events will be attenuated if no account is taken of the variability of marker values. Thus, a number of authors have studied the modelling marker data using the longitudinal models discussed above, and embedding this in a proportional hazards model relating the hazard of clinical event to the marker levels. Tsiatis et al. 73 use this approach Advances in medical statistics arising from the AIDS epidemic 127 in a two-stage procedure where CD4 counts in each risk set are first imputed using empirical Bayes estimates from a random effects model applied to longitudinal CD4 count data, and then a proportional hazards model is applied to the imputed CD4 counts and time to clinical event data. Related approaches were studied by La Valley and DeGruttola 74 and Bycott and Taylor, 75 using more general longitudinal models based on equation (4.1). Alternatives to the two-stage approach have also been developed, in which simultaneous estimation is undertaken of parameters specifying the longitudinal marker model and parameters specifying the relationship between marker levels and clinical event times. [76] [77] [78] Based on both simulations and analyses of CD4 count data, a number of authors 75, 78, 79 have concluded that joint analysis of longitudinal marker data and time to event data does indeed improve estimates of hazard ratios in proportional hazards models. A further motivation for joint analysis is the potential for more efficient estimation of time to event distributions. 80 Many other contributions have been made to the joint modelling of longitudinal markers and time-to-event data, in AIDS and other contexts, see the review paper by Hogan and Laird. 80 
Clinical trials
Antiviral therapies to treat HIV-infected patients were developed soon after the identification of HIV and this area continues to be a focus of pharmaceutical research. The sheer number of AIDS clinical trials being conducted has meant that AIDS has motivated methodological developments across most areas of clinical trials research. One important area, stimulated by the desire for more rapid assessment of AIDS therapies, is statistical investigation of the validity of surrogate endpoints based on marker measurements. In this section we review a number of AIDS-motivated developments in the validation of surrogate endpoints for clinical trials. We also briefly mention some additional methodological areas, including multiple outcome analysis motivated by the numerous conditions that define AIDS, as well as developments in clinical trial monitoring. For a more general discussion of a broad range of issues arising in AIDS clinical trials and drug development, the reader is referred to the book edited by Finkelstein and Schoenfeld. 81 
Surrogate endpoints
AIDS drug development contributed to an important shift in the process of drug approval in the USA, with the FDA initiating mechanisms for accelerated approval. The potential for quicker and less costly approval of drugs has led to an interest in surrogate endpoints in AIDS clinical trials and this has led to important advances in statistical methodology for surrogate endpoints, much of which is applicable in wider contexts. Long-term clinical endpoints of primary interest in AIDS trials include mortality, particularly for patients with advanced infection, and progression to new AIDS-defining conditions, particularly for patients with less advanced disease. Potential surrogate endpoints include changes in CD4 counts and viral load levels in response to treatment, and much interest has centred on the extent to which treatment effects on long-term endpoints such mortality and morbidity are mediated through these surrogate endpoints. Full mediation of treatment effects through surrogate endpoints would allow new drugs to be tested using surrogate endpoints alone, whereas partial mediation would imply that complete drug effects can only be assessed using clinical endpoints.
Early methodology for assessing surrogate endpoints was developed in contexts other than AIDS, 82, 83 and effectively focused on assessing the extent to which the treatment effect on clinical endpoints disappeared among patients with similar surrogate endpoint responses. This led to the 'proportion of treatment effect explained' (PTE), which is defined as the relative reduction in the treatment effect when the surrogate endpoint response is adjusted for. 83 Small relative reductions, or small PTE, are taken to indicate an inadequate surrogate endpoint, while large PTE (closer to 100%) are taken to indicate a more complete surrogate endpoint. While the PTE has been used to assess CD4 counts and viral load as surrogate endpoints, 84, 85 one of the main contributions that AIDS has made to surrogate endpoint assessment is in raising the awareness of the inherent statistical complexities and inadequacies in common methods. In other words, this is an example where statistical work generated by AIDS has placed existing methodology under closer scrutiny. Highlighting the statistical instability of the PTE metric in assessing the surrogacy of CD4 counts, Lin et al. 86 derived a method for assessing its sampling variability and associated confidence intervals. The many potential mechanisms of action of AIDS therapies, both efficacious and adverse, led DeGruttola et al. 87 to identify a number of statistical shortcomings of PTE, particularly in moderately sized trials or trials of agents with only moderate benefit. For example, when there are multiple mechanisms of treatment action, some efficacious and some adverse, the PTE can take any value including those outside the range 0-100%. Similar shortcomings were identified by Bycott and Taylor 75 in a simulation study and associated application to CD4 count data. DeGruttola et al: 87 concluded that it is very difficult to capture the effects of multiple treatment mechanisms through any single surrogate endpoint metric. This is consistent with the discussion provided by Fleming, 88 who pointed out, in the context of AIDS and cancer trials, the inherent statistical difficulties with using surrogate endpoints when treatments have multiple mechanisms of action.
In view of the AIDS-motivated developments in joint analysis of longitudinal markers and survival data, together with the focus on surrogate endpoint assessment in AIDS clinical trials, it is not surprising that a number of authors have discussed the use of these joint analyses in the surrogate endpoint assessment process. Tsiatis et al., 73 Dafni and Tsiatis 79 and Bycott and Taylor 75 have all made use of the two-stage process described in Section 4, in the context of assessing the surrogacy of CD4 counts. Both Dafni and Tsiatis 79 and Bycott and Taylor 75 conclude that this process is superior to the naïve approach in which observed unadjusted marker values are used.
The limitations associated with validating surrogate endpoints on the basis of single trials has led to methodology for meta-analysis of multiple trials, to which AIDS-related work has made significant contributions. One of the most important advances in this area is in methodology that relates the treatment effect of clinical outcomes to the treatment effect on surrogate outcomes, across clinical trials. This allows one to address the central question of to what extent the clinical outcome effect can be predicted from the surrogate outcome effect. The idea of considering the association between clinical outcome treatment effects and surrogate outcome treatment effects across trials was first proposed in the context of cancer by A'Hern et al. 89 and was subsequently considered qualitatively by Fleming 88 for CD4 counts in AIDS trials. A more quantitative and statistically rigorous methodology was developed by Daniels and Hughes, 90 building on work of Hughes et al. 91 These authors use a Bayesian model for the relationship between clinical outcome Advances in medical statistics arising from the AIDS epidemic 129 treatment effects and surrogate outcome treatment effects, with a view to assessing the reliability with which the former can be predicted by the latter. The same idea, albeit in a non-Bayesian setting, has since been taken up in other contexts, particularly cancer. Specifically, Buyse et al: 92À95 use these ideas to define alternative surrogate endpoint metrics to the PTE. Such metrics are based on trial-level surrogacy, defined by a high coefficient of determination between the trial-specific clinical outcome treatment effects and surrogate outcome treatment effects, and individual level surrogacy, defined by a high coefficient of determination between patient-specific clinical outcomes and surrogate outcomes. Under this approach a surrogate outcome is valid if both trial-and individuallevel surrogacy hold. Such methodology is currently incomplete, particularly as it relates to time-to-event endpoints that have most relevance to AIDS -thus, this may potentially be an area where AIDS problems provide motivation for future methodological developments in surrogate endpoint validation.
Monitoring and analysis
As discussed by DeMets et al., 96 the environment of intense urgency surrounding AIDS drug development, combined with the potentially serious toxicities of experimental AIDS therapies, leads to many challenges for the monitoring of AIDS clinical trials. These challenges have made AIDS a fertile area of application for general methodological developments in sequential monitoring, as well as providing the impetus for developments designed to deal with specific features of AIDS. A good example of these challenges providing motivation for improved clinical trial design and monitoring, is the development of adaptive randomization procedures, such as the play-the-winner rule, which allows a sequentially monitored trial to minimize the number of patients exposed to an inferior treatment. 97 The use of viral load responses to assess treatment effects has led to a number of papers dealing with sequential monitoring issues associated with repeated measurements. For example, Hu and Lagakos 98 consider the mean function of a repeated measures process, such as the change in viral load over time, and describe methods for sequentially monitoring such a function. An important issue in the monitoring of repeated viral load measurements is the distinction between short-and long-term treatment effects. In view of the high potential for drug resistance, the ability of a drug to suppress viral load in the short-term may be very different from its ability to achieve suppression in the long term, and this led Zackin et al. 99 to caution against relying solely on short-term responses to assess treatment effects. Leading on from this work, Marschner and Becker 100 discussed how to use short-term responses to improve the efficiency with which long-term responses are sequentially monitored. This is relevant not only for HIV viral load suppression but also for other conditions, such as cancer, where an early beneficial response could potentially be lost over time. There are many other examples of interim monitoring methodology benefiting from the motivation provided by AIDSsome additional areas include sequential analysis of multiple endpoints, 101,102 methods for early identification of inferior arms in multi-arm trials 103 and formal Bayesian inclusion of external information during the monitoring process. 104, 105 We mention two further areas concerning the analysis of treatment effects from clinical trials, in which the specific issues associated with AIDS have motivated, and are likely to continue to motivate, methodological developments. The occurrence of multiple opportunistic infections in AIDS patients, and the use of these as endpoints in clinical 130 NG Becker and IC Marschner trials, has motivated a variety of techniques for multiple, or multivariate, endpoint analysis. Of particular interest, in the context of a potentially fatal condition, are techniques for handling HIV-related mortality and the fact that observation of recurrent events is terminated on death. 106, 107 An additional area of particular importance in AIDS trials is analysis in the presence of non-compliance, since many therapies for AIDS are highly sensitive to the time spent on treatment. 108, 109 6 Modelling and analyses for infectious diseases
As HIV is transmissible one might expect substantial overlap in the statistical methodology that applies to HIV and other infectious diseases. In reality the overlap is modest, because HIV/AIDS has several unique characteristics. Epidemic periods for most infectious diseases are relatively short, making it reasonable to assume that parameters of transmission and disease progression remain constant over the duration of a typical epidemic. Furthermore, the health outcome of many infectious diseases is a morbidity event rather than death. In contrast, the duration of the HIV epidemic is very long, because the incubation period usually lasts several years, and death is a common eventual outcome. In response to the HIV threat the community has responded, during the course of the epidemic, to generate changes in parameter values over time. A consequence is that standard statistical methods and models for infectious diseases are often less relevant to HIV data. There are, however, some HIV-related motivated developments that are of interest to infectious disease epidemiology and we review some of these under the headings of inference and modelling.
Inferences from infectious disease data
One development of interest is concerned with inferences about the infectiousness function, a concept described in Chapter 3 of Becker. 110 For reasons of convenience, early work on epidemics focused on Markovian epidemic models in which the distribution of the infectious period is exponential and the force of infection exerted by individuals during their infectious periods is a constant. Little effort has been put into getting away from this simplifying assumption. In reality it is likely that the rate of shedding infectious agents is a fairly smooth function, rather than a step-function with a single non-zero value, and estimation of its functional form is of interest. In the HIV context there is particular interest in how the infectiousness of an individual changes over time because the period over which an infected individual can infect others is potentially very long. This has encouraged study of the infectiousness function. Observations on viral load suggest that the risk that an HIV-infected person transmits the disease to a sexual partner is high for a period soon after being infected. It is thought that there then follows a long period during which the risk of transmission is relatively low, but the risk of transmission increases again as the infective approaches the time of AIDS diagnosis. Attempts to make inferences about the pattern in the level of infectiousness have been made with references to partner studies by Jewell and Shiboski, 111, 112 Kim and Lagakos, 113 Shiboski and Jewell 114 and Jewell et al.
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There are applications of the idea and methods of back-calculation to problems a little different from that for which the method was designed. Here we mention one where Advances in medical statistics arising from the AIDS epidemic 131 back-calculation is used to provide a method for estimating parameters of an epidemic model and in the next section we mention another where back-calculation is used to assist a modelling project.
It is very difficult to estimate parameters of disease transmission models because the processes of infection and disease progression are observed incompletely. Various, somewhat ad hoc, methods have been devised to overcome the difficulties. A recent approach 116 uses a method of back-calculation to reconstruct the infection process from the observed case-detection process and then, under the assumption that the reconstructed process is the realized infection curve, estimates parameters from the explicit expressions for maximum likelihood estimates available for complete data. Assessment of the performance of the method indicates that it provides estimates of practical value and is particularly valuable for highly infectious diseases, where the probability of everyone being infected is high, a situation for which no satisfactory methods of estimation existed.
Modelling disease transmission
The unique features of HIV/AIDS also impact on the relevance of standard transmission models to describe the dynamics of HIV infection. Again there is the fact that the parameter values are changing over time for HIV, as a result of intervention and changes in behaviour. However, the description of HIV transmission is also complicated by the fact that there are multiple modes of transmission. Changes over time have been different for different modes of transmission, with some, such as medically acquired infection, essentially being eliminated. Attempts at modelling the dynamics of the HIV epidemic have tended to restrict attention to a specific exposure category. This is not entirely satisfactory, since some transmission between exposure categories is likely to occur, but is worthwhile when the majority of cases arise in a single exposure category or when one exposure category is known to be fairly self-contained. An added difficulty is that the exposure categories with relatively high incidences in developed nations have been sensitive categories such as 'men who have sex with men' and 'intravenous drug users'. For such categories it is very difficult to obtain reliable data on quantities, such as number at risk, which are crucial for reliable modelling. These difficulties explain why the method of back-calculation is often preferred over transmission models as a method for estimating disease incidence and for making projections of AIDS incidences.
Despite these difficulties modelling work on the dynamics of HIV transmission contains some examples with features that have the potential to impact on epidemic modelling in general. An example is the inclusion of pair formation and variable infectivity into the dynamic description of the transmission process as in Kretzschmar and Dietz. 117 Another example is the allowance made for the substantial diversity reported in the number of sexual partners as in Anderson. 118 A refreshing feature of HIV modelling is that it is more often formulated with the purpose of addressing a specific disease, or public health-related research question. In other words, models tend to be the tool used to address the research issue, rather than the model being the focus of the study. For example, West and Thompson 119 use mathematical models to investigate the magnitude and duration of the effect that the HIV epidemic may have on tuberculosis in the United States.
We have mentioned the difficulties associated with transmission models for HIV that have caused other methods, such as back-calculation, to be the preferred method to address the study question. However, one task for which transmission models are essential 132 NG Becker and IC Marschner is the assessment of methods of intervention. When a government has approved considerable funding on a strategy for the control of HIV transmission, it is inevitable that they ask 'how would the epidemic have progressed if we had not intervened?'. This speculative 'what if we had not intervened' scenario can only be addressed by the use of a transmission model. A precise answer to the question is, of course, unlikely but there is no doubt that this question will be addressed and it is important that epidemic modellers be involved in this exercise. A transmission model with parameter values that obtain when there is no intervention is able to suggest the path that the epidemic would have taken if there had been no intervention. The task of assigning parameters for this purpose was addressed by Hurley et al. 120 in two steps. First, values were assigned to any parameters about which studies reported in the literature provide reasonably reliable information. For example, the incubation distribution can be considered known. Then, in principle, the remaining parameters can be assigned values by fitting the transmission model to the HIV incidences realized during the pre-intervention period of the epidemic. As the realized HIV incidences are not observed, Hurley et al. 120 use back-calculation to reconstruct them and fitted the transmission model to the reconstructed HIV incidences over the pre-intervention period. Then, having a transmission model with pre-intervention parameter values assigned, the model can be used to indicate the path the epidemic would have taken if no intervention had occurred. This illustrates a potential role for the method of back-calculation in the assessment of methods for the control of outbreaks of other diseases.
Disease screening and prevention
From the numerous other areas where work motivated by AIDS has made a substantial contribution to medical statistics we mention just two, chosen because vaccination and health screening are such important areas of health management.
Vaccine studies for communicable diseases
Vaccination tends to be the best way of controlling disease transmission and as a result many studies are conducted to determine the 'effectiveness' of a vaccines. Nevertheless, the traditional measure of vaccine efficacy
proportion of vaccinated individuals who become cases proportion of unvaccinated individuals who become cases ð7:1Þ
introduced by Greenwood and Yule, 121 does not make allowance for the fact that a disease can be transmitted from person to person. In contrast, work concerned with HIV vaccine trials has focused more directly on disease transmission, especially the work on trials involving partners. As a consequence, methods for assessing the effectiveness of vaccines for transmissible diseases in general are being enhanced substantially by HIV-motivated research. The need to focus on transmissible diseases arises, in part, from the fact that vaccines have both a direct and an indirect effect on the control of disease transmission in a community, see Haber. 122 The direct effect arises from the fact that a vaccine protects the vaccinee from being infected. The indirect effect arises from the fact that vaccination of some individuals in the community decreases the number of cases and thereby the force Advances in medical statistics arising from the AIDS epidemic 133 of infection acting on all individuals is decreased. This means that vaccination also offers some protection to community members who have not been vaccinated. Furthermore, a vaccine can also lower the infectiousness of vaccinated individuals, should they happen to be infected, relative to an unvaccinated individual. This also reduces the force of infection acting on individuals and it is important to assess how effective a vaccine is at lowering infectivity.
An important mode of HIV transmission is sexual contacts and therefore the HIVrelated work has brought the discussion of vaccine trials into the domain of sexually transmissible diseases. For example, Rida, 123 Datta et al. 124 and Longini et al. 125 consider vaccine trials for individuals and their steady partners, allowing for disease transmission and aiming to measure the reduction in both susceptibility and infectiousness induced by vaccination. Estimates, standard errors and confidence intervals are given for these measures of effectiveness. The assumptions are somewhat specific to sexually transmissible diseases, however, the ideas extend to vaccine trials for other transmissible diseases where we might observe household outbreaks, as is noted by Halloran 126 in the discussion to Rida's paper.
A nice aspect of the HIV-related work is its focus on the design of vaccine trials. The emphasis of statistical contributions is too often restricted to methods of analysis and it is refreshing to see a focus on the statistical design of studies.
An aspect of vaccine effectiveness that has received relatively little statistical attention is the possibility that a vaccine may give different levels of protection against different strains of the infecting agent. This issue arises for HIV infection since HIV-1 is very diverse and the analysis by Gilbert et al:;
127 which allows for this diversity, has relevance for other diseases, such as influenza and pneumococcal infection.
Screening for disease when prevalence is low
Screening for HIV deserves consideration for a number of reasons. One might wish to estimate the prevalence of HIV infection in the population, or in a specific exposure category. One might wish to ensure that donated blood is safe for transfusion recipients or wish to promote early detection of HIV-infected individuals. Such HIV-driven concerns have stimulated work on screening designs and methods of analysis for screening data. One of the more interesting ideas is that of applying tests of HIV-positivity to pooled samples of blood products. In low prevalence areas most tests on samples from individuals will be true negatives and there will be many false-positive test results, making the detection of actual cases costly. The idea that tests on pooled serum samples may be a costeffective alternative has a long history, see Dorfman 128 and Chiang and Reeves, 129 but there was relatively little study of the statistical issues associated with this problem until the emergence of HIV, with its good diagnostic tests. Since the late 1980s there has been a steady stream of statistical research papers, as is pointed out by Lan et al.
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At the first stage of a multi-stage design, pools of sera are tested for presence or absence of disease. The second stage consists of dividing the positive pools of the first stage into a number of smaller pools. Any pools diagnosed as positive at a stage are subdivided into smaller pools for testing at the next stage. The rationale is that with low prevalence of disease many pools will be negative, whereby the number of tests required to isolate positive individual samples is reduced substantially. The idea is not only attractive because it is a cost-effective way of screening. When prevalence is low and diagnostic tests are not 100% reliable one can actually achieve lower error rates in diagnoses compared to testing each individual sample, see Litvak et al. 131 Design issues centre around how many specimen samples should be pooled at each stage and how many stages are appropriate. The latter is of interest when the aim is to estimate disease prevalence, which can be estimated from data on a single-stage design, see Thompson. 132 The estimate of Thompson is generalized to k stages by Brookmeyer, 133 motivated by a desire to estimate HIV incidence rates. While these methods are often discussed with reference to serum samples it is acknowledged that they apply equally to urine sample, for example. Other diseases that might benefit from these screening methods include hepatitis C, performanceenhancing drugs and sexually transmitted diseases. Gastwirth and Johnson 134 demonstrate that group testing can be a useful tool as a quality control method when screening a large population for an infection or trait.
